Feriani 1998.

Methods	Study design: parallel, open label RCT Study duration: not reported Follow‐up period: 24 weeks
Participants	Countries: Germany Setting: multicentre (14 sites) Adult patients on CAPD (prevalent) who were free of peritonitis for at least 4 weeks preceding the study commencement. Phase II study (24 weeks) Number: treatment group (37); control group (36) Median age, range (years): treatment group (54.5, 18.6‐78); control group (55, 21.27‐79.4) Sex (M/F): treatment group (17/20); control group (20/16) Exclusion criteria: not reported
Interventions	Treatment group 34 mmol/L bicarbonate‐buffered solution Control group 35 mmol/L lactate‐buffered PD solution
Outcomes	RRF UF Subjective assessment ‐ symptoms Adverse events
Notes	Grant from Fresenius Phase I study data only available from conference abstract 36 patients left at the end of phase I of study ‐ no explanation provided
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised centrally and separately for each study centre and block randomisation in steps of four used
Allocation concealment (selection bias)	Low risk	No specific information provided. However central randomisation with probable low risk of selection bias
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label, may have affected symptom assessment
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	High risk	Large number of participants missing between two phases of study that are not accounted for in the paper: 18/123 (14.6%) for 12 weeks; 4/73 (5.5%) for 24 week study
Selective reporting (reporting bias)	Low risk	All relevant clinical outcomes reported
Other bias	Unclear risk	Insufficient information to permit judgement